{"product_id":"cris-marketing-mix","title":"(CRIS) Curis, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Curis, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotion tactics to show how it competes and reaches customers. The page includes a real preview\/sample of the analysis so you can evaluate style and content before buying; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmavusertib Phase 1\/2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmavusertib is Curis, Inc.'s lead oncology asset by development stage, an oral small molecule in clinical-stage testing. It is in Phase 1\/2 studies for non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes, giving Curis a multi-indication pipeline driver. The asset supports the Product and Promotion side of Curis’s 4P mix by pairing a convenient oral format with late early-stage clinical momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCI-8993 VISTA Antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCI-8993 is a monoclonal antibody program built to block V-domain Ig suppressor of T cell activation, or VISTA, a checkpoint tied to immune evasion. It fits Curis, Inc.'s immuno-oncology focus by targeting a high-value pathway in cancer care, but it remains a development-stage asset, not a marketed product.\u003c\/p\u003e\n\u003cp\u003eFor the 2025\/2026 period, its value sits in pipeline optionality: if VISTA blockade shows clinical signal, it could expand Curis, Inc.'s shot at combination therapy deals and future oncology revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFimepinostat HDAC PI3K\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc.'s Fimepinostat is an oral dual HDAC and PI3K inhibitor aimed at MYC-altered diffuse large B-cell lymphoma, a biomarker-defined cancer subgroup. The product strategy is tight: target a clear genetic marker, focus on a hard-to-treat blood cancer, and use an oral format that can support outpatient use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCA-170 and CA-327\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCA-170 is Curis, Inc.’s oral small molecule for advanced solid tumors and lymphomas, while CA-327 is still in the pre-IND phase. Together, they widen Curis, Inc.’s pipeline beyond its lead hematology assets and give the company more shots at data-driven catalysts.\u003c\/p\u003e\n\u003cp\u003eIn Product terms, these programs target distinct cancer settings and support a broader development story. CA-170 is the nearer-term clinical asset, and CA-327 adds early-stage optionality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCA-170: oral oncology small molecule\u003c\/li\u003e\n\u003cli\u003eTargets solid tumors and lymphomas\u003c\/li\u003e\n\u003cli\u003eCA-327: pre-IND stage\u003c\/li\u003e\n\u003cli\u003eBroadens Curis, Inc. pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eErivedge Hedgehog Inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eErivedge is Curis, Inc.’s oral hedgehog-pathway inhibitor for advanced basal cell carcinoma, a cancer where Hedgehog signaling is active in over 90% of cases. Curis markets it with F. Hoffmann-La Roche Ltd. and Genentech Inc., so product reach depends on that partnered commercial setup.\u003c\/p\u003e\n\u003cp\u003eIn the 4P mix, Product is a targeted small-molecule therapy with a clear niche and specialty-use profile; place and promotion are largely partner-led, while price is tied to oncology reimbursement and access rules.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: advanced basal cell carcinoma\u003c\/li\u003e\n\u003cli\u003eRoute: oral, once-daily therapy\u003c\/li\u003e\n\u003cli\u003eMechanism: hedgehog pathway inhibition\u003c\/li\u003e\n\u003cli\u003ePartnered with Roche and Genentech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris’ Oncology Pipeline Anchored by Emavusertib and Erivedge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc.'s Product mix is built around oncology pipeline assets, led by emavusertib, a clinical-stage oral small molecule in Phase 1\/2 for NHL, AML, and MDS. Fimepinostat, CA-170, and CA-327 add biomarker-led and early-stage optionality, while Erivedge remains a partnered, marketed niche therapy in advanced basal cell carcinoma.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eKey use\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmavusertib\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003eNHL, AML, MDS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eErivedge\u003c\/td\u003e\n\u003ctd\u003eMarketed\u003c\/td\u003e\n\u003ctd\u003eAdvanced BCC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a concise, company-specific breakdown of Curis, Inc.’s Product, Price, Place, and Promotion strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly clarifies Curis, Inc.’s 4Ps, easing analysis overload and supporting fast, confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary and reputable sources to validate Curis, Inc. assumptions and speed investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLexington Massachusetts HQ\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. is headquartered in Lexington, Massachusetts, and that site serves as its corporate base. Strategic, scientific, and administrative work is directed there, keeping leadership and R\u0026amp;D close to the Boston biotech cluster. For a biotech company, a single HQ helps keep decision-making fast and operating costs tight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States Clinical Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. keeps its United States clinical focus tight: its cancer pipeline is built around U.S.-based, clinical-stage development, so trials, data readouts, and investigator sites are centered in American oncology centers. That gives the company direct access to the U.S. research base and the FDA path for future commercialization. In practice, its market reach is mainly shaped by U.S. trial execution, regulatory milestones, and oncology partner networks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrial Site Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. relies on hospital and research sites to move emavusertib and its other clinical programs, so the trial network is the main place where these development-stage products reach patients. In its 2024 pipeline, emavusertib was still in Phase 1\/2 studies, which means site access, investigator enrollment, and trial execution drive progress more than retail distribution. The tighter the site network, the faster Curis can recruit and generate data for each study.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoche Genentech Channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris uses a partner-led place strategy for Erivedge: Roche and Genentech handle co-development and commercialization, while Curis does not rely on direct retail distribution. Erivedge was FDA-approved in 2012, and this channel keeps access tied to Roche Genentech’s oncology network rather than Curis-owned sales routes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoche Genentech runs commercialization\u003c\/li\u003e\n\u003cli\u003eCuris avoids direct retail distribution\u003c\/li\u003e\n\u003cli\u003eErivedge approval year: 2012\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAurigene Collaboration Route\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc. uses the Aurigene Discovery Technologies Limited partnership as an external route for small molecule research, development, and possible commercialization, which lowers in-house burden and widens its development reach. The setup gives Curis a partner-led path to advance assets beyond discovery while sharing execution risk and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal R\u0026amp;D support\u003c\/li\u003e\n\u003cli\u003eSmall molecule focus\u003c\/li\u003e\n\u003cli\u003eShared development risk\u003c\/li\u003e\n\u003cli\u003eCommercial pathway access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Stays Lean in Lexington, Reaching Patients Through Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. keeps Place centered on one U.S. base: Lexington, Massachusetts, while its clinical work stays in U.S. oncology sites. That supports fast coordination, FDA-facing trials, and tight control of a small biotech footprint.\u003c\/p\u003e\n\u003cp\u003eFor market access, Curis uses partners, not a broad sales network: Roche Genentech commercializes Erivedge, approved in 2012, and Aurigene supports external R\u0026amp;D. So its reach comes from trial sites and partner channels, not owned distribution.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace lever\u003c\/th\u003e\n\u003cth\u003eLatest fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eLexington, Massachusetts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eErivedge\u003c\/td\u003e\n\u003ctd\u003eFDA-approved 2012; Roche Genentech commercializes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline access\u003c\/td\u003e\n\u003ctd\u003eU.S. oncology trial sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eCuris, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Curis, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully detailed, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSEC Filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. uses SEC filings as its main investor promotion channel, with Form 10-K, 10-Q, and 8-K disclosures showing pipeline progress, collaboration terms, and financial results. These filings give analysts the hard data they need on cash use, operating losses, and program status, so they matter more than ads or broad brand campaigns. For a small biotech, that disclosure stream is a core promotion tool for trust and valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Updates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. uses clinical trial updates to show pipeline progress, especially from its Phase 1\/2 work and any pre-IND milestones. In biotech, even one new readout can matter because it helps de-risk a program and signal scientific momentum. That message is critical for investors, since development-stage value often hinges on clinical data, not sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePress Releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris uses press releases to announce research and partnership updates, with a focus on product candidates like emavusertib and key strategic agreements. The company uses these notices to keep investors informed about pipeline activity and trial progress, which matters for a small biotech with limited revenue. In 2025, that kind of communication is still a core way Curis signals development milestones and partner news.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner Announcements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc. uses partner announcements with Roche, Genentech, and Aurigene as public promotion assets. These 3 collaborations widen reach and add third-party credibility, which helps Curis signal scientific validation without heavy paid media. They also show Curis can advance compounds through external alliances, a key proof point for a small biotech.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 named partner collaborations\u003c\/li\u003e\n\u003cli\u003eBoosts credibility and reach\u003c\/li\u003e\n\u003cli\u003eSignals alliance-driven progress\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInvestor Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris’s promotion is investor-facing, not consumer-led: it speaks to shareholders, analysts, and oncology specialists, which fits a clinical-stage biotech model. Investor relations is the main channel for news on pipeline progress, trial data, and financing needs, since value depends on clinical milestones more than product ads. That makes the message B2B, evidence-based, and tied to capital-markets credibility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets investors and analysts\u003c\/li\u003e\n\u003cli\u003eFocuses on pipeline updates\u003c\/li\u003e\n\u003cli\u003eSupports biotech funding needs\u003c\/li\u003e\n\u003cli\u003eBuilds trust through disclosures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Relies on SEC Filings and Trial News to Win Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc.’s promotion is investor-led: SEC filings, trial updates, and press releases carry the message on pipeline progress, cash use, and partnership news. In 2025, this matters more than brand ads because value depends on clinical data, not sales. The company also uses partner names like Roche, Genentech, and Aurigene to add credibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC filings\u003c\/td\u003e\n\u003ctd\u003eCore investor channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial news\u003c\/td\u003e\n\u003ctd\u003eSignals de-risking\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo Public List Prices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc.’s pipeline assets—Emavusertib, CI-8993, Fimepinostat, CA-170, and CA-327—are still investigational, so no public consumer list prices are disclosed. Pricing is not set like a retail product during development; it depends on trial results, FDA approval, dosing, and reimbursement. Curis reported $2.0 million in total revenue for 2025, underscoring that these candidates are not yet commercial products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-Sold Erivedge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eErivedge is co-developed and co-marketed with Roche and Genentech, so commercial pricing sits with the partnered oncology channel, not Curis. Curis is not a direct consumer seller for this product, which limits its control over list price, discounts, and access terms. In Curis filings, Erivedge remains a partnered asset rather than a company-run retail product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelopment Stage Economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris’s price is really a valuation of clinical progress, not unit sales, because the Company still has no approved product revenue. In 2025, its economics were driven by R\u0026amp;D spend, trial readouts, and the chance of moving compounds to later-stage milestones. So the market prices Curis on pipeline value, cash runway, and de-risking events, not shelf pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaboration-Based Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc. uses collaboration-based revenue because it is a small clinical-stage biotech with no broad product sales base. Licensing, co-development, and commercialization deals are the main way it turns science into cash, so partner payments and milestones matter more than volume sales.\u003c\/p\u003e\n\u003cp\u003eThat model fits the sector: many early biotechs trade future upside for lower upfront risk and outside funding. For Curis, the revenue stream is tied to deal terms, program progress, and partner execution, so cash flow can swing sharply by quarter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing drives monetization\u003c\/li\u003e\n\u003cli\u003eCo-development shares risk\u003c\/li\u003e\n\u003cli\u003eMilestones can move revenue\u003c\/li\u003e\n\u003cli\u003ePartner execution affects cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology Reimbursement Path\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology pricing is mostly set by payer coverage, prior auth, and site-of-care rules, so a launch can face high rebates and tight access. Cancer drugs are often routed through specialty pharmacy or hospital outpatient channels; in the U.S., oncology spend was about $230B in 2024, showing how reimbursement drives net price. Curis, Inc.’s pipeline is still pre-broad-commercial, so no market pricing has been established yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess drives net price\u003c\/li\u003e\n\u003cli\u003eSpecialty channels are common\u003c\/li\u003e\n\u003cli\u003eCuris, Inc. has no launch price yet\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Has No Set Launch Price Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. has no set launch price yet because its pipeline remains investigational, so price is tied to trial progress, FDA approval, and payer access. In 2025, Curis reported $2.0 million of total revenue, showing it still has no commercial product pricing. Erivedge is partnered with Roche and Genentech, so pricing there sits with the partner channel, not Curis.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice factor\u003c\/th\u003e\n\u003cth\u003eCuris, Inc.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch pricing\u003c\/td\u003e\n\u003ctd\u003eNot established\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eErivedge pricing control\u003c\/td\u003e\n\u003ctd\u003ePartnered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234229985545,"sku":"cris-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/cris-marketing-mix.webp?v=1785715840","url":"https:\/\/dcfanalyst.com\/products\/cris-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}